ENSC VS INM Stock Comparison

Performance

ENSC
10/100

ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

INM
10/100

INM returned -87.71% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

ENSC
25/100

ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

INM
11/100

INM receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

ENSC
33/100

ENSC has missed earnings 3 times in the last 20 quarters.

INM
10/100

INM has missed earnings 7 times in the last 20 quarters.

Profit

ENSC
27/100

Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.

INM
10/100

Out of the last 20 quarters, INM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ENSC
50/100

ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

INM
54/100

INM has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ensysce Biosciences, Inc. Common Stock Summary

Nasdaq / ENSC

Healthcare

Biotechnology

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

InMed Pharmaceuticals Inc. Common Shares Summary

Nasdaq / INM

Healthcare

Biotechnology

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Power up your portfolio